

Analyst

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

1
2
3 **Loss of the preferential control over the striato-nigral direct pathway by striatal NMDA**
4 **receptors in a rat model of Parkinson's disease**
5
6
7

8 Michele Morari^{1,2*} and Martina Fantin^{1,2}
9

10
11
12
13 ¹Department of Medical Sciences, Section of Pharmacology, ²Neuroscience Center and National
14 Institute of Neuroscience, University of Ferrara, Ferrara (Italy)
15
16
17
18
19
20
21
22

23 ***Author for correspondence:**
24

25 Michele MORARI
26

27 Department of Medical Sciences
28 Section of Pharmacology,
29 University of Ferrara
30 via Fossato di Mortara 17-19
31 44121 FERRARA (ITALY)
32 phone: +39-0532-455210
33 fax: +39-0532-455205
34 E-mail: m.morari@unife.it
35
36
37
38

39 **ABBREVIATIONS**
40

41 DA dopamine
42 DLS dorsolateral striatum
43 GLU glutamate
44 GP globus pallidus
45 6-OHDA 6-hydroxydopamine
46 SNr substantia nigra reticulata
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

By using multi-probe microdialysis we previously demonstrated that endogenous glutamate differentially regulates the activity of the striatal output pathways in vivo, through N-methyl-D-aspartate (NMDA) receptors containing the GluN2A or GluN2B subunits. Using the same approach, we presently investigate whether reverse dialysis of NMDA in striatum differentially affects GABA release in striatum and in striatal target areas, i.e. globus pallidus (GP) and substantia nigra reticulata (SNr). Moreover, we ask whether this control is altered under parkinsonian conditions. Intra-striatal NMDA perfusion (10 min) evoked GABA release more potently in SNr (1-100 μM) than other regions (10-100 μM), suggesting a preferential control over striato-nigral projection neurons. Intra-striatal NMDA more potently stimulated glutamate levels in striatum (1-100 μM) and SNr (1-10 μM) than GP (10 μM). Striatal dopamine denervation with 6-hydroxydopamine caused a leftward shift in the NMDA concentration-response curve. Intra-striatal NMDA elevated GABA levels at 0.1 μM (all regions) and 1 μM (striatum and GP only), but not higher concentrations, indicating that, compared to naïve animals, the GABA response in SNr was attenuated. Attenuation of the glutamate response was also observed in SNr (NMDA effective only at 0.1 μM). Conversely, the glutamate response in GP was widened (NMDA effective in the 0.1-1 μM range).

We conclude that NMDA preferentially stimulates the activity of the striato-nigral direct pathway under physiological conditions. In Parkinson's disease, dopamine loss compromises the NMDA ability to stimulate striato-nigral neurons, thus shifting the NMDA control towards the striato-pallidal ones.

Key words: direct pathway, GABA, glutamate, microdialysis, NMDA, 6-OHDA.

Introduction

Striatal N-methyl-D-aspartate (NMDA) receptors are a promising target in the therapy of neuro-psychiatric disorders such as Parkinson's disease (PD)¹⁻³, Huntington's disease⁴, dystonia⁵, and drug addiction⁶. The striatal region is particularly enriched of NMDA receptors, which appear to be unevenly distributed across the different neuronal populations⁷⁻⁹. The NMDA receptor is a heteromer composed of two obligatory GluN1 subunits and two GluN2 (A-D) or, less commonly, GluN3 (A-C) subunits¹⁰⁻¹². The most abundant subtype combinations (GluN1/GluN2A and GluN1/GluN2B) are expressed to approximately the same extent on medium-sized spiny neurons (MSNs) projecting to substantia nigra reticulata (SNr) and globus pallidus (GP)⁸, i.e. those neurons giving rise to the so-called direct and indirect striatal output pathways, respectively¹³⁻¹⁵.

According to the current model of basal ganglia (BG) functioning¹³⁻¹⁵, these two pathways exert a functionally opposing influence over nigro-thalamic neurons (i.e. the basal ganglia output) and motor function. MSNs which preferentially express D1 receptors and co-release GABA with substance P and dynorphin (the direct pathway), monosynaptically inhibit tonically-active nigro-thalamic GABA neurons, causing disinhibition of thalamo-cortical afferents, and movement initiation^{16, 17}. Conversely, MSNs which express D2 receptors and co-release GABA with enkephalins inhibit GABA neurons in GP (GP externalis in primates), which, in turn, disinhibit glutamate (GLU) neurons located in subthalamic nucleus (STN). These neurons send excitatory projections to SNr, stimulating the firing of nigro-thalamic neurons and inhibiting movement¹⁷. More recent evidence indicates that simultaneous, rather than alternate, activation of these two pathways is essential to a correct action selection and expression of motor function, since the direct pathway promotes movement while the indirect one inhibits competing motor programmes¹⁸⁻²⁰.

Striatal output neurons are activated by cortical and thalamic glutamatergic inputs^{21, 22}, but the contribution of NMDA receptors under both physiological and pathological *in vivo* conditions is yet to be clarified. To this purpose, we have adopted dual or triple-probe microdialysis technique in awake rats, implanting one probe in dorsolateral striatum (DLS) and the others in GP and/or SNr.

1
2
3 This approach allowed us to locally deliver NMDA or NMDA receptor antagonists (either broad-
4 spectrum or subunit-selective) into the striatum, and simultaneously measure changes of GABA
5 release in target areas ²³⁻²⁶. Indeed, previous dual- probe microdialysis studies had shown that
6 manipulation of striatal environment resulted in coherent changes of GABA release in GP and SNr,
7 suggesting that GABA dynamics could probe the activity of striato-pallidal and striato-nigral MSNs
8 ²⁷⁻³¹. To integrate our previous studies, we now specifically examine whether reverse dialysis of
9 increasing NMDA concentrations in DLS causes differential activation of striato-nigral or striato-
10 pallidal MSNs, and whether such control is altered under parkinsonian conditions.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Materials and Methods

Male Sprague-Dawley rats (150 g; Harlan Italy, S. Pietro al Natisone, Italy) were kept under controlled lighting conditions (12 hr light/dark cycle) and given food and water *ad libitum*. The experimental protocols were approved by the Ethical Committee of the University of Ferrara and the Italian Ministry of University (licenses 94-2007-B and 194-2008-B). Adequate measures were taken to minimize animal pain and discomfort, and to limit the number of animals used.

6-OHDA lesion

Unilateral lesion of dopamine (DA) neurons was induced in isoflurane-anesthetized rats as previously described^{23, 32}. Eight micrograms of 6-OHDA (in 4 μ l of saline containing 0.02% ascorbic acid) were stereotaxically injected according to the following coordinates from bregma: anteroposterior (AP) -4.4 mm; mediolateral (ML) -1.2 mm; ventrodorsal (VD) -7.8 mm below dura³³. The rotational model³⁴ was used to select the rats that had been successfully lesioned. Two weeks after surgery, rats were injected with amphetamine (5 mg/kg, i.p., dissolved in saline) and only those rats performing more than seven ipsilateral turns per minute were enrolled in the study. This behavior has been associated with >95 % loss of striatal DA terminals³⁵ and extracellular DA levels³². Experiments were performed 6-8 weeks after lesion.

Microdialysis experiments

Dual probe microdialysis was performed as previously described^{27, 32}. Two probes of concentric design were stereotaxically implanted under isoflurane anaesthesia in the right DLS (3 mm dialysing membrane, AN69, Gambro Industries, Meyzieu, France) and ipsilateral SNr (1 mm) or GP (1.5 mm) according to the following coordinates from bregma and the dural surface³³: DLS; AP +1.0, ML -3.5, VD -6; GP, AP -1.3, ML -3.3, VD -6.5; SNr, AP -5.5, ML -2.2, VD -8.3. Forty-eight hours after surgery, probes were perfused with a modified Ringer solution (CaCl₂ 1.2 mM; KCl 2.7 mM; NaCl 148 mM; MgCl₂ 0.85 mM) at a 3 μ l/min flow rate. After 6 h rinsing, samples were collected every 10 min. At least four baseline samples were collected before NMDA perfusion

1
2
3 (0.01-100 μM ; 10 min) through the probe implanted in DLS. At the end of the experiments, animals
4
5 were sacrificed and the correct placement of the probes was verified histologically.
6
7

8 *Amino acid analysis*

9
10 Endogenous GLU and GABA levels were measured by high-performance liquid chromatography
11
12 (HPLC) coupled to fluorometric detection according to ^{23, 24}. Briefly, 30 μl sample were pipetted
13
14 into glass microvials and placed in a thermostated (4°C) Triathlon autosampler (Spark Holland,
15
16 Emmen, The Netherlands). Forty microliters of o-phthaldialdehyde/boric acid solution were added
17
18 to each sample, and 60 μl of the solution injected onto a 5-C18 Chromsep analytical column (3 mm
19
20 inner diameter, 10 cm length; Chrompack, Middelburg, Netherlands) perfused at a flow rate of 0.48
21
22 ml/min (Beckman 125 pump; Beckman Instruments, Fullerton, CA, USA) with a mobile phase
23
24 containing 0.1 M sodium acetate, 10% methanol and 2.2% tetrahydrofuran (pH 6.5). GLU and
25
26 GABA were detected by means of a fluorescence spectrophotometer FP-2020 Plus (Jasco, Tokyo,
27
28 Japan) with the excitation and the emission wavelengths set at 370 and 450 nm respectively. GLU
29
30 and GABA retention time were ~ 3.5 and ~ 17.5 min, respectively. The limits of detection for GLU
31
32 and GABA were ~ 1 and ~ 0.5 nM, respectively.
33
34
35
36
37

38 *Data presentation and statistical analysis*

39
40 Data (mean \pm SEM) from microdialysis experiments are reported as percentage of basal value
41
42 (calculated as the mean of two samples before treatment). Mean neurotransmitter levels in the
43
44 dialysate (in nM; not corrected for in vitro probe recovery) have been reported in text and Figure
45
46 legends. Statistical analysis was performed on area-under-the curve (AUC) values by one-way
47
48 ANOVA followed by the Newman-Keuls test for multiple comparisons. P values < 0.05 were
49
50 considered to be statistically significant.
51
52
53

54 *Materials*

55
56 6-OHDA hydrobromide, D-amphetamine sulfate, and NMDA (free acid; molecular weight 147.13)
57
58 were purchased from Tocris (Bristol, UK). 6-OHDA was dissolved in saline containing 0.02 %
59
60

1
2
3 ascorbic acid, D-amphetamine in saline and NMDA in Ringer (final pH adjusted to 7.3 with
4
5 NaOH).
6
7
8
9

10 **Results**

11 **Intrastriatal NMDA perfusion in naïve rats**

12
13 To investigate whether striatal NMDA receptors regulate striato-pallidal and striato-nigral MSNs,
14
15 reverse dialysis of NMDA was performed in the DLS of naïve rats, and GABA and GLU release
16
17 monitored in DLS and its projection areas, namely the ipsilateral GP and SNr.
18
19

20
21 *DLS.* Basal GABA and GLU levels in DLS were 15.1 ± 2.5 nM (n=48) and 191.6 ± 17.9 nM (n=47),
22
23 respectively. ANOVA revealed that intrastriatal perfusion with NMDA elevated both GABA
24
25 ($F_{4,48}=3.87$, $p=0.0084$) and GLU ($F_{4,47}=8.56$, $p<0.0001$) levels in the dialysate (Fig. 1A-B). Posthoc
26
27 analysis showed that NMDA stimulated GABA levels at 10 and 100 μ M, and GLU levels in the 1-
28
29 100 μ M concentration range.
30
31

32
33 *GP.* Basal GABA and GLU levels in GP were 15.1 ± 1.4 nM (n=37) and 134.6 ± 19.0 nM (n=40),
34
35 respectively. ANOVA revealed that intrastriatal perfusion with NMDA evoked both GABA
36
37 ($F_{4,42}=7.37$, $p<0.0001$) and GLU ($F_{4,44}=3.75$, $p=0.0105$) release in GP (Fig. 2A-B). Posthoc analysis
38
39 revealed an effect of 10 μ M and 100 μ M NMDA on pallidal GABA release. Conversely, the effect
40
41 of NMDA on pallidal GLU release was limited to the 1 μ M concentration.
42
43

44
45 *SNr.* Basal GABA and GLU levels in SNr were 13.9 ± 0.8 nM (n=43) and 138.2 ± 11.7 nM (n=48),
46
47 respectively. ANOVA revealed that intrastriatal perfusion with NMDA evoked GABA ($F_{4,43}=5.74$,
48
49 $p=0.0010$) and GLU ($F_{4,46}=9.52$, $p<0.0001$) release in SNr (Fig. 3A-B). NMDA evoked nigral
50
51 GABA release in the 1-100 μ M concentration range, whereas it evoked nigral GLU release at 1 and
52
53 10 μ M, the 100 μ M concentration being ineffective.
54
55
56
57
58
59

60 **Intrastriatal NMDA perfusion in hemiparkinsonian rats**

To investigate whether removal of endogenous DA could affect the response to exogenous NMDA, we performed reverse dialysis of NMDA in the DA-depleted striatum of hemiparkinsonian rats.

DLS. Basal GABA levels in the DA-depleted DLS of hemiparkinsonian rats (12.1 ± 1.2 nM) were not significantly different from naïve animals. Conversely, GLU levels were significantly reduced by 65% ($t=4.61, df=67, p<0001$). ANOVA revealed that NMDA elevated both GABA ($F_{3,25}=6.72, p=0.0018$) and GLU ($F_{3,27}=4.27, p=0.0136$) levels (Fig. 4A-B). However, the effect of NMDA on GABA release was evident at 0.1 and 1 μ M, whereas that on GLU release only at 0.1 μ M. In a few animals ($n=4$), 0.01 μ M NMDA was also perfused. At this concentration, NMDA failed to affect local amino acid levels (not shown).

GP. Basal GABA (9.4 ± 1.8 nM; $n=32$) and GLU (86.7 ± 19.8 nM; $n=30$) levels in the GP of hemiparkinsonian rats were not significantly different from naïve animals. ANOVA revealed that NMDA elevated both GABA ($F_{3,21}=8.87, p=0.0005$) and GLU ($F_{3,24}=5.02, p=0.0076$) pallidal levels (Fig. 5A-B). The effect of NMDA on both amino acids was significant at 0.1 and 1 μ M, but not at higher concentrations. The lower (0.01 μ M) NMDA concentration was also ineffective ($n=4$; not shown).

SNr. Basal GABA (11.2 ± 1.1 nM; $n=32$) and GLU (103.1 ± 28.6 nM; $n=31$) levels in the SNr of hemiparkinsonian rats were not significantly different from naïve animals. ANOVA revealed that intrastriatal NMDA elevated both GABA ($F_{3,23}=10.81, p=0.0001$) and GLU ($F_{3,23}=5.39, p=0.0059$) nigral levels (Fig. 6A-B). The effect of NMDA on both amino acids was significant at 0.1 but not higher or lower (0.01 μ M; $n=4$; not shown) concentrations.

Discussion

The present study shows that stimulation of striatal NMDA receptors leads to the increase of GABA release in both SNr and GP, suggesting that NMDA receptors can activate both striatal output pathways²⁴. Nonetheless, drawing a complete NMDA concentration-response curve revealed that,

1
2
3 under normal conditions, NMDA evoked GABA release more potently in SNr than GP (Tab. 1),
4
5 suggesting a preferential control over striato-nigral MSNs.
6
7

8 Cortico-striatal and thalamo-striatal glutamatergic afferents synapse onto both populations of
9
10 striatal MSNs^{21, 22}. However, not only striatal MSNs but also striatal interneurons express the
11
12 NMDA receptor^{7, 8}. As a matter of fact, being tonically active, interneurons might be the first target
13
14 of NMDA since membrane depolarization would relieve NMDA channel from Mg⁺⁺ block and
15
16 favour its opening upon binding of NMDA to its receptor. Since striatal interneurons powerfully
17
18 regulate the excitability of striatal output pathways³⁶⁻³⁸, the greater responsitivity of nigral vs
19
20 pallidal GABA to intrastriatal NMDA might rely both on the intrinsic characteristics of the two
21
22 populations of striatal MSNs and the striatal microcircuitry. Indeed, although striato-pallidal MSNs
23
24 are thought to be more excitable than the striato-nigral ones³⁹, cortico-striatal responses, and their
25
26 NMDA (APV-sensitive) components, are larger and more prolonged in striato-nigral MSNs^{40, 41}. In
27
28 addition, striatal output neurons differently respond to inputs originating from GABA
29
30 interneurons. In fact, GABA inputs drive both excitation and inhibition to striato-nigral MSNs, but
31
32 only inhibition to the striato-pallidal ones⁴⁰. A greater effect of NMDA along the striato-nigral
33
34 pathway would predict a predominantly stimulatory impact of NMDA receptor activation on motor
35
36 function. Indeed, microinjection of NMDA in the dorsal striatum of naïve rats evoked contraversive
37
38 rotation⁴², a behavioural index of direct pathway activation¹⁷.
39
40
41
42
43
44

45 The ability of intrastriatal NMDA to stimulate nigral and pallidal GABA release was dramatically
46
47 altered by removal of endogenous DA, as in the 6-OHDA hemilesioned rat model of PD. In
48
49 particular, DA depletion enhanced the potency of NMDA and cancelled the preferential effect on
50
51 nigral GABA, since NMDA evoked GABA release yet at 0.1 µM in all structures analysed (Tab. 2).
52
53 Considering the voltage-dependence of the opening of the NMDA channel, such increase in potency
54
55 might be explained on the basis of the increased excitability of striatal MSNs which has been
56
57 consistently observed after DA depletion⁴³⁻⁴⁸. This increase of excitability is thought to compensate
58
59 for the dramatic pruning of cortico-striatal and thalamo-striatal contacts which follows DA loss⁴⁹⁻⁵²,
60

1
2
3 although whether striato-pallidal MSNs only ⁵² or both striato-pallidal and striato-nigral MSNs are
4 affected by pruning in the 6-OHDA rat model remains controversial ⁵¹. In addition, other factors
5 might contribute to the changes in neurons excitability observed in striatal MSNs after DA
6 denervation, such as an imbalance in cortical inputs ⁵³, striatal interneuron modulation ⁵³⁻⁵⁵,
7 enhanced GLU release and responsiveness to GLU inputs ⁴⁸ or altered synaptic plasticity at cortico-
8 striatal afferents ^{56, 57}. Not last, it is well known that DA denervation results in the loss of a D2
9 inhibitory influence on GLU inputs at striato-pallidal MSNs, and of a D1 facilitatory influence on
10 GLU inputs at striato-nigral MSNs ⁵⁸⁻⁶¹.

11
12
13
14
15
16
17
18
19
20
21
22 In vivo ⁵³ and in vitro ⁴¹ electrophysiology on identified MSNs has clarified that only striato-pallidal
23 MSNs exhibit an increase in responsiveness to cortical inputs following DA loss, since striato-
24 nigral MSNs show opposite changes. Our in vivo data are in line with these findings, showing that
25 intrastriatal NMDA perfusion in the DA-denervated striatum evoked GABA release in GP and DLS
26 in a wider range of concentrations (0.1-1 μ M) than in SNr (0.1 μ M), possibly indicating that DA
27 loss has compromised the ability of NMDA to stimulate striato-nigral MSNs. DA denervation was
28 accompanied by a significant reduction of basal striatal GLU levels. This is consistent with previous
29 studies in 6-OHDA hemilesioned rats ⁶², although at variance with the majority of microdialysis
30 studies showing either increase ⁶³⁻⁶⁵ or no change ^{32, 66-70} of GLU levels in the DA-denervated
31 striatum. Nonetheless, time-dependent changes in dialysate GLU levels, i.e. increase at 1 month and
32 reduction at 3 months after DA-denervation, have been reported in 6-OHDA hemilesioned rats ⁷¹.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
These changes have been inversely correlated to GLU content in nerve terminals, although the
underlying mechanism remains elusive ⁷¹.

Increases in GABA release were usually associated with increases in GLU release in the three areas
examined, with two exceptions: i) NMDA (1 μ M) elevated GLU but not GABA in DLS; ii) NMDA
(100 μ M) elevated GABA without affecting GLU in both GP and SNr. Although GABA and GLU
can be co-released in some areas of the CNS (for a review see ⁷²), no such evidence has been yet
provided for GABA afferents in DLS, GP or SNr. Therefore, other factors should be called into

1
2
3 play. For instance, as far as the local effects of NMDA in DLS are concerned, indirect modulation
4 might be involved. Indeed, we failed in demonstrating the presence of NMDA receptors facilitating
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

play. For instance, as far as the local effects of NMDA in DLS are concerned, indirect modulation might be involved. Indeed, we failed in demonstrating the presence of NMDA receptors facilitating GLU release on striatal glutamatergic afferents (i.e. NMDA autoreceptors)⁶⁷. Conversely, we showed that the ability of intrastriatal NMDA to elevate striatal GLU was attenuated by blockade of striatal D1 and NK1 receptors, or action potential propagation, suggesting that the increase of striatal GLU was due to activation of intra- or extrastriatal loops⁶⁷. The present study points to the activation of the direct striato-nigral pathway at the basal ganglia-thalamo-cortico-basal ganglia loop, since NMDA (1 μ M) elevated striatal GLU concurrently with nigral GABA (and nigral GLU). Also the increase in GLU release in GP might be explained on the basis of the activation of extrastriatal loops. Indeed, stimulation of striato-pallidal neurons would cause inhibition of pallido-subthalamic neurons and disinhibition of the subthalamo-pallidal glutamatergic projection, leading to a feedback increase in GLU release in GP¹⁵. Consistently, blockade of GABA_A receptors in STN prevented the increase in pallidal GLU induced by intrastriatal neurotensin administration⁷³. Therefore, the enhanced pallidal response to intrastriatal NMDA observed in hemiparkinsonian rats is consistent with an enhancement of the NMDA-induced activity along the indirect pathway⁶⁶. The reason why intrastriatal perfusion of 100 μ M NMDA stimulated GABA but not GLU release in GP remains a matter of conjecture. It is possible that higher NMDA concentrations cause a higher increase in the firing rate of striato-pallidal MSNs, with greater release of GABA and co-transmitters (enkephalins), leading to inhibition of pallidal GLU release. Indeed, enkephalins are the endogenous ligands of delta opioid receptor, and delta opioid receptor stimulation can reduce GLU levels^{74, 75}.

The changes in the GABA responses in SNr and GP to intrastriatal perfusion of NMDA adds to previous microdialysis studies, and strengthen the evidence of a change in the NMDA receptor mediated control of striatal output pathways in the parkinsonian brain. Reverse dialysis of (R)-[(S)-1-(4-bromo-phenyl)-ethylamino]-(2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-yl)-methyl]-phosphonic acid (NVP-AAM077)⁷⁶, a preferential GluN2A antagonists, or (R-(R*,S*)- α -(4-hydroxyphenyl)- β -

1
2
3 methyl-4-(phenylmethyl)-1-piperidinepropanol (Ro 25-6981)⁷⁷, a selective GluN2B antagonist, in
4
5 the DLS of naïve rats caused inhibition of GABA release in GP and SNr, respectively²⁴. Moreover,
6
7 reverse dialysis of Ro 25-6981 in the DA-depleted striatum failed to reduce GABA release in SNr,
8
9 whereas intrastriatal NVP-AAM077 became more potent in inhibiting GABA release in GP^{23, 25}.
10
11 Based on these microdialysis data, we proposed that GluN2A and GluN2B receptors preferentially
12
13 regulate the indirect and direct pathway, respectively^{23, 24}. Indeed, these data are consistent with the
14
15 opposite changes in responsiveness of striato-nigral and striato-pallidal MSNs to cortical inputs
16
17 after DA loss (hypo- and hyperresponsivity, respectively)^{41, 53}. Moreover, they parallel
18
19 morphological studies showing that DA loss results in the loss of synaptic GluN2B receptors and in
20
21 the increase in the GluN2A/GluN2B ratio⁷⁸⁻⁸⁰.
22
23
24
25
26

27 **Concluding remarks**

28
29 Dual-probe microdialysis shows that reverse dialysis of NMDA in striatum evokes GABA release
30
31 more potently in SNr than GP. This preferential control is regulated by endogenous DA since
32
33 striatal DA denervation causes an increase in NMDA potency along with selective attenuation of
34
35 the nigral response. Overall, it appears that striatal NMDA receptors preferentially regulate the
36
37 striato-nigral pathway under physiological conditions, and that this control is unbalanced in favour
38
39 of the striato-pallidal pathway in the absence of endogenous DA. Abnormal function of striatal
40
41 NMDA receptors has been found to be associated with symptoms of PD (for reviews see^{3, 81, 82}).
42
43
44
45 The present study suggests that changes in the NMDA receptor mediated control of striatal output
46
47 pathways might contribute to these motor disturbances. Therapeutic strategies aimed at correcting
48
49 such imbalance might therefore consider opposite interventions, e.g, via negative and positive
50
51 allosteric modulators⁸³, at striatal GluN2A and GluN2B receptors regulating striato-pallidal and
52
53 striato-nigral MSNs^{23, 25}, respectively.
54
55
56
57
58
59
60

Figure legends

Fig. 1. Effect of NMDA on striatal GABA and GLU release in naïve rats. Effect of reverse dialysis of NMDA (1-100 $\mu\text{mol/L}$; 10 min, black bar) in the dorsolateral striatum (DLS) on local GABA and GLU extracellular levels. Data are expressed as percentages \pm SEM of basal pre-treatment levels (calculated as mean of the two samples before the treatment) and are means of 6-8 rats per group. Basal GABA and GLU levels (nmol/L), calculated as the mean of all rats enrolled, were 15.1 ± 2.5 (n=48) and 191.6 ± 17.9 (n=47), respectively. Statistical analysis was performed on the area-under-the-curve values (AUC; arbitrary units, Panel B) using 1-way ANOVA followed by the Newman-Keuls test. * $p < 0.05$, ** $p < 0.01$ different from Ringer

Fig 2. Effect of NMDA on pallidal GABA and GLU release in naïve rats. Effect of reverse dialysis of NMDA (1-100 $\mu\text{mol/L}$; 10 min, open bar) in the dorsolateral striatum (DLS) on GABA and GLU extracellular levels in ipsilateral globus pallidus (GP). Data are expressed as percentages \pm SEM of basal pre-treatment levels (calculated as mean of the two samples before the treatment) and are means of 6-8 rats per group. Basal GABA and GLU levels (nmol/L), calculated as the mean of all rats enrolled, were 15.1 ± 1.4 nmol/L and 134.6 ± 19.0 , respectively. Statistical analysis was performed on the area-under-the-curve values (AUC; arbitrary units, Panel B) using 1-way ANOVA followed by the Newman-Keuls test. * $p < 0.05$, ** $p < 0.01$ different from Ringer

Fig 3. Effect of NMDA on nigral GABA and GLU release in naïve rats. Effect of reverse dialysis of NMDA (1-100 $\mu\text{mol/L}$; 10 min, open bar) in the dorsolateral striatum (DLS) on GABA and GLU extracellular levels in ipsilateral substantia nigra reticulata (SNr). Data are expressed as percentages \pm SEM of basal pre-treatment levels (calculated as mean of the two samples before the treatment) and are means of 6-8 rats per group. Basal GABA and GLU levels (nmol/L), calculated as the mean of all rats enrolled, were 13.9 ± 0.8 (n=43) and 138.2 ± 11.7 (n=48), respectively. Statistical analysis

1
2
3 was performed on the area-under-the-curve values (AUC; arbitrary units, Panel B) using 1-way
4 ANOVA followed by the Newman-Keuls test. * $p < 0.05$, ** $p < 0.01$ different from Ringer
5
6
7
8
9

10 **Fig. 4.** Effect of NMDA on striatal GABA and GLU release in hemiparkinsonian rats. Effect of
11 reverse dialysis of NMDA (1-100 $\mu\text{mol/L}$; 10 min, black bar) in the dopamine-depleted dorsolateral
12 striatum (DLS) of 6-OHDA hemilesioned rats on local GABA and GLU extracellular levels. Data
13 are expressed as percentages \pm SEM of basal pre-treatment levels (calculated as mean of the two
14 samples before the treatment) and are means of 6-8 rats per group. Basal GABA and GLU levels
15 (nmol/L), calculated as the mean of all rats enrolled, were 12.1 ± 1.2 and 67.9 ± 8.0 ($n=22$ each),
16 respectively. Statistical analysis was performed on the area-under-the-curve values (AUC; arbitrary
17 units, Panel B) using 1-way ANOVA followed by the Newman-Keuls test. * $p < 0.05$, ** $p < 0.01$
18 different from Ringer
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33

34 **Fig. 5.** Effect of NMDA on pallidal GABA and GLU release in hemiparkinsonian rats. Effect of
35 reverse dialysis of NMDA (1-100 $\mu\text{mol/L}$; 10 min, open bar) in the dopamine-depleted dorsolateral
36 striatum (DLS) of 6-OHDA hemilesioned rats on GABA and GLU extracellular levels in ipsilateral
37 globus pallidus (GP). Data are expressed as percentages \pm SEM of basal pre-treatment levels
38 (calculated as mean of the two samples before the treatment) and are means of 6-8 rats per group.
39 Basal GABA and GLU levels (nmol/L), calculated as the mean of all rats enrolled, were 9.4 ± 0.8
40 ($n=32$) and 86.7 ± 19.8 nmol/L ($n=30$), respectively. Statistical analysis was performed on the area-
41 under-the-curve values (AUC; arbitrary units, Panel B) using 1-way ANOVA followed by the
42 Newman-Keuls test. * $p < 0.05$, ** $p < 0.01$ different from Ringer
43
44
45
46
47
48
49
50
51
52
53
54
55
56

57 **Fig. 6.** Effect of NMDA on nigral GABA and GLU release in hemiparkinsonian rats. Effect of
58 reverse dialysis of NMDA (1-100 $\mu\text{mol/L}$; 10 min, open bar) in the dopamine-depleted dorsolateral
59 striatum (DLS) of 6-OHDA hemilesioned rats on GABA and GLU extracellular levels in ipsilateral
60

1
2
3 substantia nigra reticulata (SNr). Data are expressed as percentages \pm SEM of basal pre-treatment
4
5 levels (calculated as mean of the two samples before the treatment) and are means of 6-8 rats per
6
7 group. Basal GABA and GLU levels (nmol/L), calculated as the mean of all rats enrolled, were
8
9 11.2 \pm 1.1 (n=32) and 103.1 \pm 28.6 (n=31), respectively. Statistical analysis was performed on the
10
11 area-under-the-curve values (AUC; arbitrary units, Panel B) using 1-way ANOVA followed by the
12
13 Newman-Keuls test. *p<0.05, **p<0.01 different from Ringer
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Comparative effects induced by reverse dialysis of NMDA (0.1-100 μ M, 10 min) in the dorsolateral striatum (DLS) of naive rats on GABA and glutamate levels in DLS, ipsilateral globus pallidus (GP) and substantia nigra reticulata (SNr).

NMDA (μ M)	DLS		GP		SNr	
	GABA	glutamate	GABA	glutamate	GABA	glutamate
0.1	ne	ne	ne	ne	ne	ne
1	ne	+	ne	ne	+	+
10	+	+	+	+	+	+
100	+	+	+	ne	+	ne

+ = increase

ne = not effective

Table 2. Comparative effects induced by reverse dialysis of NMDA (0.1-100 μ M, 10 min) in the dorsolateral striatum (DLS) of 6-OHDA hemilesioned rats on GABA and glutamate levels in DLS, ipsilateral globus pallidus (GP) and substantia nigra reticulata (SNr).

NMDA (μ M)	DLS		GP		SNr	
	GABA	glutamate	GABA	glutamate	GABA	glutamate
0.01	ne	ne	ne	ne	ne	ne
0.1	+	+	+	+	+	+
1	+	ne	+	+	ne	ne
10	ne	ne	ne	ne	ne	ne
100	nt	nt	nt	nt	nt	nt

+ = increase

ne = not effective

nt = not tested

REFERENCES

1. T. N. Chase, J. D. Oh and P. J. Blanchet, *Neurology*, 1998, 51, S30-35.
2. T. N. Chase, J. D. Oh and S. Konitsiotis, *J Neurol*, 2000, 247 Suppl 2, II36-42.
3. P. J. Hallett and D. G. Standaert, *Pharmacol Ther*, 2004, 102, 155-174.
4. M. M. Fan and L. A. Raymond, *Prog Neurobiol*, 2007, 81, 272-293.
5. Y. Avshalumov, S. E. Sander, F. Richter, K. Porath, M. Hamann, C. Bode, T. Kirschstein, R. Kohling and A. Richter, *Exp Neurol*, 2014, 261C, 677-684.
6. Y. Y. Ma, C. Cepeda and C. L. Cui, *Int Rev Neurobiol*, 2009, 89, 131-146.
7. G. B. Landwehrmeyer, D. G. Standaert, C. M. Testa, J. B. Penney, Jr. and A. B. Young, *J Neurosci*, 1995, 15, 5297-5307.
8. D. G. Standaert, I. K. Friberg, G. B. Landwehrmeyer, A. B. Young and J. B. Penney, Jr., *Brain Res Mol Brain Res*, 1999, 64, 11-23.
9. D. G. Standaert, C. M. Testa, A. B. Young and J. B. Penney, Jr., *J Comp Neurol*, 1994, 343, 1-16.
10. P. Paoletti and J. Neyton, *Curr Opin Pharmacol*, 2007, 7, 39-47.
11. P. Paoletti, C. Bellone and Q. Zhou, *Nat Rev Neurosci*, 2013, 14, 383-400.
12. A. Sanz-Clemente, R. A. Nicoll and K. W. Roche, *Neuroscientist*, 2013, 19, 62-75.
13. M. R. DeLong, *Trends Neurosci*, 1990, 13, 281-285.
14. R. L. Albin, A. B. Young and J. B. Penney, *Trends Neurosci*, 1989, 12, 366-375.
15. G. E. Alexander and M. D. Crutcher, *Trends Neurosci*, 1990, 13, 266-271.
16. J. M. Deniau and G. Chevalier, *Brain Res*, 1985, 334, 227-233.
17. A. V. Kravitz, B. S. Freeze, P. R. Parker, K. Kay, M. T. Thwin, K. Deisseroth and A. C. Kreitzer, *Nature*, 2010, 466, 622-626.
18. B. S. Freeze, A. V. Kravitz, N. Hammack, J. D. Berke and A. C. Kreitzer, *J Neurosci*, 2013, 33, 18531-18539.
19. J. W. Mink, *Arch Neurol*, 2003, 60, 1365-1368.
20. G. Cui, S. B. Jun, X. Jin, M. D. Pham, S. S. Vogel, D. M. Lovinger and R. M. Costa, *Nature*, 2013, 494, 238-242.
21. N. R. Wall, M. De La Parra, E. M. Callaway and A. C. Kreitzer, *Neuron*, 2013, 79, 347-360.
22. I. Huerta-Ocampo, J. Mena-Segovia and J. P. Bolam, *Brain Struct Funct*, 2014, 219, 1787-1800.
23. M. Fantin, Y. P. Auberson and M. Morari, *J Neurochem*, 2008, 106, 957-968.
24. M. Fantin, M. Marti, Y. P. Auberson and M. Morari, *J Neurochem*, 2007, 103, 2200-2211.
25. O. S. Mabrouk, F. Mela, M. Calcagno, M. Budri, R. Viaro, A. Dekundy, C. G. Parsons, Y. P. Auberson and M. Morari, *ACS chemical neuroscience*, 2013, 4, 808-816.
26. M. Morari, W. T. O'Connor, U. Ungerstedt, C. Bianchi and K. Fuxe, *Neuroscience*, 1996, 72, 89-97.
27. M. Morari, W. T. O'Connor, M. Darvelid, U. Ungerstedt, C. Bianchi and K. Fuxe, *Neuroscience*, 1996, 72, 79-87.
28. W. Sommer, R. Rimondini, W. O'Connor, A. C. Hansson, U. Ungerstedt and K. Fuxe, *Proc Natl Acad Sci U S A*, 1996, 93, 14134-14139.
29. S. Ferre, W. T. O'Connor, K. Fuxe and U. Ungerstedt, *J Neurosci*, 1993, 13, 5402-5406.
30. Z. B. You, M. Herrera-Marschitz, I. Nylander, M. Goiny, W. T. O'Connor, U. Ungerstedt and L. Terenius, *Neuroscience*, 1994, 63, 427-434.
31. Z. B. You, I. Nylander, M. Herrera-Marschitz, W. T. O'Connor, M. Goiny and L. Terenius, *Neuroscience*, 1994, 63, 415-425.
32. M. Marti, F. Mela, C. Bianchi, L. Beani and M. Morari, *J Neurochem*, 2002, 83, 635-644.
33. G. Paxinos and C. Watson, *The rat brain in stereotaxic coordinates*, Academic Press, Sydney ; Orlando, 2nd edn., 1986.
34. U. Ungerstedt and G. W. Arbuthnott, *Brain Res*, 1970, 24, 485-493.
35. M. Marti, C. Trapella, R. Viaro and M. Morari, *J Neurosci*, 2007, 27, 1297-1307.
36. T. Koos and J. M. Tepper, *Nat Neurosci*, 1999, 2, 467-472.
37. E. Galarraga, S. Hernandez-Lopez, A. Reyes, I. Miranda, F. Bermudez-Rattoni, C. Vilchis and J. Bargas, *J Neurosci*, 1999, 19, 3629-3638.
38. S. N. Szydlowski, I. Pollak Dorocic, H. Planert, M. Carlen, K. Meletis and G. Silberberg, *J Neurosci*, 2013, 33, 1678-1683.
39. E. Valjent, J. Bertran-Gonzalez, D. Herve, G. Fisone and J. A. Girault, *Trends Neurosci*, 2009, 32, 538-547.
40. B. J. Vizcarra-Chacon, M. A. Arias-Garcia, M. B. Perez-Ramirez, E. Flores-Barrera, D. Tapia, R. Drucker-Colin, J. Bargas and E. Galarraga, *BMC Neurosci*, 2013, 14, 60.
41. E. Flores-Barrera, B. J. Vizcarra-Chacon, D. Tapia, J. Bargas and E. Galarraga, *Front Syst Neurosci*, 2010, 4, 15.
42. P. K. Thanos, K. Jhamandas and R. J. Beninger, *Brain Res*, 1992, 589, 55-61.

- 1
2
3 43. E. S. Nisenbaum, E. M. Stricker, M. J. Zigmond and T. W. Berger, *Brain Res*, 1986, 398, 221-230.
4 44. K. Y. Tseng, F. Kasanetz, L. Kargieman, L. A. Riquelme and M. G. Murer, *J Neurosci*, 2001, 21, 6430-6439.
5 45. M. T. Chen, M. Morales, D. J. Woodward, B. J. Hoffer and P. H. Janak, *Exp Neurol*, 2001, 171, 72-83.
6 46. W. Schultz and U. Ungerstedt, *Exp Brain Res*, 1978, 33, 159-171.
7 47. E. Galarraga, J. Bargas, D. Martinez-Fong and J. Aceves, *Neurosci Lett*, 1987, 81, 351-355.
8 48. P. Calabresi, N. B. Mercuri, G. Sancesario and G. Bernardi, *Brain*, 1993, 116 (Pt 2), 433-452.
9 49. T. H. McNeill, S. A. Brown, J. A. Rafols and I. Shoulson, *Brain Res*, 1988, 455, 148-152.
10 50. C. A. Ingham, S. H. Hood and G. W. Arbuthnott, *Brain Res*, 1989, 503, 334-338.
11 51. R. M. Villalba and Y. Smith, *Front Neuroanat*, 2010, 4, 133.
12 52. M. Day, Z. Wang, J. Ding, X. An, C. A. Ingham, A. F. Shering, D. Wokosin, E. Ilijic, Z. Sun, A. R. Sampson,
13 E. Mugnaini, A. Y. Deutch, S. R. Sesack, G. W. Arbuthnott and D. J. Surmeier, *Nat Neurosci*, 2006, 9, 251-
14 259.
15 53. N. Mallet, B. Ballion, C. Le Moine and F. Gonon, *J Neurosci*, 2006, 26, 3875-3884.
16 54. A. H. Gittis and A. C. Kreitzer, *Trends Neurosci*, 2012, 35, 557-564.
17 55. N. Dehorter, C. Guigoni, C. Lopez, J. Hirsch, A. Eusebio, Y. Ben-Ari and C. Hammond, *J Neurosci*, 2009, 29,
18 7776-7787.
19 56. P. Calabresi, B. Picconi, A. Tozzi and M. Di Filippo, *Trends Neurosci*, 2007, 30, 211-219.
20 57. A. C. Kreitzer and R. C. Malenka, *Neuron*, 2008, 60, 543-554.
21 58. C. Cepeda, N. A. Buchwald and M. S. Levine, *Proc Natl Acad Sci U S A*, 1993, 90, 9576-9580.
22 59. M. Morari, W. T. O'Connor, U. Ungerstedt and K. Fuxe, *Eur J Pharmacol*, 1994, 256, 23-30.
23 60. M. S. Levine, K. L. Altemus, C. Cepeda, H. C. Cromwell, C. Crawford, M. A. Ariano, J. Drago, D. R. Sibley
24 and H. Westphal, *J Neurosci*, 1996, 16, 5870-5882.
25 61. S. Hernandez-Lopez, J. Bargas, D. J. Surmeier, A. Reyes and E. Galarraga, *J Neurosci*, 1997, 17, 3334-3342.
26 62. M. S. Reid, M. Herrera-Marschitz, J. Kehr and U. Ungerstedt, *Acta Physiol Scand*, 1990, 140, 527-537.
27 63. U. Tossman, J. Segovia and U. Ungerstedt, *Acta Physiol Scand*, 1986, 127, 547-551.
28 64. N. Jonkers, S. Sarre, G. Ebinger and Y. Michotte, *Brain Res*, 2002, 926, 149-155.
29 65. N. Lindfors and U. Ungerstedt, *Neurosci Lett*, 1990, 115, 248-252.
30 66. L. Ferraro, W. T. O'Connor, S. Beggiato, M. C. Tomasini, K. Fuxe, S. Tanganelli and T. Antonelli, *Eur J*
31 *Neurosci*, 2012, 35, 207-220.
32 67. M. Marti, M. Manzalini, M. Fantin, C. Bianchi, L. Della Corte and M. Morari, *J Neurochem*, 2005, 93, 195-
33 205.
34 68. Z. B. You, M. Herrera-Marschitz, E. Pettersson, I. Nylander, M. Gojny, H. Z. Shou, J. Kehr, O. Godukhin, T.
35 Hokfelt, L. Terenius and U. Ungerstedt, *Neuroscience*, 1996, 74, 793-804.
36 69. F. Galeffi, L. Bianchi, J. P. Bolam and L. Della Corte, *Eur J Neurosci*, 2003, 18, 856-868.
37 70. J. Abarca and G. Bustos, *Neurochem Int*, 1999, 35, 19-33.
38 71. C. K. Meshul, N. Emre, C. M. Nakamura, C. Allen, M. K. Donohue and J. F. Buckman, *Neuroscience*, 1999,
39 88, 1-16.
40 72. T. S. Hnasko and R. H. Edwards, *Annual review of physiology*, 2012, 74, 225-243.
41 73. L. Ferraro, T. Antonelli, W. T. O'Connor, K. Fuxe, P. Soubrie and S. Tanganelli, *J Neurosci*, 1998, 18, 6977-
42 6989.
43 74. O. S. Mabrouk, M. Volta, M. Marti and M. Morari, *J Neurochem*, 2008, 107, 1647-1659.
44 75. O. S. Mabrouk, R. Viaro, M. Volta, A. Ledonne, N. Mercuri and M. Morari, *J Neurosci*, 2014, 34, 12953-
45 12962.
46 76. Y. P. Auberson, H. Allgeier, S. Bischoff, K. Lingenhoehl, R. Moretti and M. Schmutz, *Bioorg Med Chem Lett*,
47 2002, 12, 1099-1102.
48 77. G. Fischer, V. Mutel, G. Trube, P. Malherbe, J. N. Kew, E. Mohacsi, M. P. Heitz and J. A. Kemp, *J Pharmacol*
49 *Exp Ther*, 1997, 283, 1285-1292.
50 78. A. W. Dunah, Y. Wang, R. P. Yasuda, K. Kameyama, R. L. Huganir, B. B. Wolfe and D. G. Standaert, *Mol*
51 *Pharmacol*, 2000, 57, 342-352.
52 79. M. Mellone and F. Gardoni, *Eur J Pharmacol*, 2013, 719, 75-83.
53 80. F. Gardoni, B. Picconi, V. Ghiglieri, F. Polli, V. Bagetta, G. Bernardi, F. Cattabeni, M. Di Luca and P.
54 Calabresi, *J Neurosci*, 2006, 26, 2914-2922.
55 81. V. Sgambato-Faure and M. A. Cenci, *Prog Neurobiol*, 2012, 96, 69-86.
56 82. T. N. Chase and J. D. Oh, *Trends Neurosci*, 2000, 23, S86-91.
57 83. B. M. Costa, M. W. Irvine, G. Fang, R. J. Eaves, M. B. Mayo-Martin, D. A. Skifter, D. E. Jane and D. T.
58 Monaghan, *J Pharmacol Exp Ther*, 2010, 335, 614-621.
59
60




Figure 1




Figure 2




Figure 3




Figure 4




Figure 5





Figure 6

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Changes in the striatal NMDA receptor-mediated control over striatofugal pathways in Parkinson's disease, as revealed by dual-probe microdialysis

106x79mm (96 x 96 DPI)